Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEPAVAC: Anti-HAV Immunisation in HIV-1 Infected Patients
NCT00190242Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2003
- Primary completion
- Oct 2006
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Hepatitis A virus vaccine in hepatitis A (HAV) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Percentage of patients with anti-HAV antibodies > 20 mUI/ml at 7 months. Started Jun 2003; status: completed.
02
Drugs
Hepatitis A virus vaccine
03
Conditions
hepatitis A (HAV)
Beyond the preview
Go deeper on NCT00190242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00190242.